Romidepsin, also known as Istodax, is an anticancer agent used in cutaneous T-cell lymphoma (CTCL) and other peripheral T-cell lymphomas (PTCLs). Romidepsin is a natural product obtained from the bacteria Chromobacterium violaceum, and works by blocking enzymes known as histone deacetylases, thus inducing apoptosis. It is sometimes referred to as depsipeptide, after the class of molecules to which it belongs. Romidepsin is branded and owned by Gloucester Pharmaceuticals, now a part of Celgene.

CAS：128517-07-7
中文别名：FK228 罗米地辛;
英文别名：Chromadax;Istodax;Romidepsin (FK228,depsipeptide);Romidepsin;FK-228;Depsipeptide;(1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone;
分子式：C24H36N4O6S2
分子量：540.696
精确质量：540.208
Psa：193.3
Logp：2.7448

UNII：CX3T89XQBK

密度：1.174g/cm3
沸点：942.8ºC at 760 mmHg
闪点：524ºC
折射率：1.529
蒸汽压：0mmHg at 25°C